OPKO Health/$OPK
1D1W1MYTD1Y5YMAX
Capital at risk
About OPKO Health
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
- Ticker
- $OPK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,275
- Headquarters
- Miami, United States
- Website
- www.opko.com
OPKO Health Metrics
BasicAdvanced
$1.2B
-
-$0.09
1.50
-
Price and volume
Market cap
$1.2B
Beta
1.5
52-week high
$1.73
52-week low
$0.98
Average daily volume
2.9M
Financial strength
Current ratio
3.349
Quick ratio
2.651
Long term debt to equity
0.317
Total debt to equity
0.336
Interest coverage (TTM)
-3.73%
Profitability
EBITDA (TTM)
-78.172
Gross margin (TTM)
19.47%
Net profit margin (TTM)
-12.40%
Operating margin (TTM)
-28.56%
Effective tax rate (TTM)
8.71%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-5.52%
Return on equity (TTM)
-5.88%
Valuation
Price to revenue (TTM)
2.068
Price to book
0.98
Price to tangible book (TTM)
38.68
Price to free cash flow (TTM)
-9.072
Free cash flow yield (TTM)
-11.02%
Free cash flow per share (TTM)
-0.172
Growth
Revenue change (TTM)
-11.47%
Earnings per share change (TTM)
-63.39%
3-year revenue growth (CAGR)
-12.18%
10-year revenue growth (CAGR)
-5.79%
3-year earnings per share growth (CAGR)
-30.48%
10-year earnings per share growth (CAGR)
-8.96%
What the Analysts think about OPKO Health
Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Analyst projections of the future price of OPKO Health stock.
Bulls say / Bears say
The Pharmaceutical segment delivered revenue of $42.9 million in Q2 2026 versus $40.7 million in Q2 2025, representing a 5.5 percent year-over-year increase driven by higher volumes in Spain and Mexico and favorable foreign exchange impacts. (GlobeNewswire)
Operating income turned positive at $0.8 million in Q2 2026 compared to an operating loss of $28.7 million in Q2 2025, underscoring improved cost efficiencies and stronger core operations. (GlobeNewswire)
OPKO Health issued full-year 2026 revenue guidance of $560 million to $585 million, signaling confidence in sustained growth across its pharmaceutical and diagnostics segments. (AP News)
Diagnostics segment service revenue declined to $74.5 million in Q2 2026 from $101.1 million in Q2 2025, a 26.3 percent drop reflecting the impact of the oncology assets divestiture and softening test demand. (GlobeNewswire)
Despite narrowing losses, OPKO reported a net loss of $8.4 million (EPS $0.01) in Q2 2026, highlighting ongoing unprofitability. (GlobeNewswire)
In connection with its amended Nicoya agreement, OPKO received an initial tranche of Series A-2 Preferred Shares and plans a second equity issuance in Q3 2026, posing potential dilution risks. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
OPKO Health Financial Performance
Revenues and expenses
OPKO Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
OPKO Health News
AllArticlesVideos
Funds containing OPKO Health
AllEURUSDGBP
Fund name | Fund size | $OPK weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.